These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1959381)

  • 1. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.
    Druzgala P; Wu WM; Bodor N
    Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate.
    Bodor N; Loftsson T; Wu WM
    Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea.
    Reddy IK; Khan MA; Wu WM; Bodor NS
    J Ocul Pharmacol Ther; 1996; 12(2):159-67. PubMed ID: 8773932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.
    Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H
    J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate.
    Soliman OAE; Mohamed EAM; El-Dahan MS; Khatera NAA
    AAPS PharmSciTech; 2017 May; 18(4):1228-1241. PubMed ID: 27469220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.
    Bodor N; Wu WM; Murakami T; Engel S
    Pharm Res; 1995 Jun; 12(6):875-9. PubMed ID: 7667193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38.
    Cavet ME; Glogowski S; Lowe ER; Phillips E
    J Ocul Pharmacol Ther; 2019 Jun; 35(5):291-300. PubMed ID: 30907685
    [No Abstract]   [Full Text] [Related]  

  • 9. Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation.
    Schopf L; Enlow E; Popov A; Bourassa J; Chen H
    Ophthalmol Ther; 2014 Dec; 3(1-2):63-72. PubMed ID: 25134493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation.
    Bodor N; Murakami T; Wu WM
    Pharm Res; 1995 Jun; 12(6):869-74. PubMed ID: 7667192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Distribution and pharmacokinetics of 20S-ginsenoside Rg3 eyeointment in rabbit eye].
    Liu JH; Lu D; Liu JP; Li PY
    Yao Xue Xue Bao; 2005 Mar; 40(3):258-61. PubMed ID: 15952600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid.
    Comstock TL; Sheppard JD
    Expert Opin Pharmacother; 2018 Mar; 19(4):337-353. PubMed ID: 29430976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loteprednol etabonate: comparison with other steroids in two models of intraocular inflammation.
    Howes JF; Baru H; Vered M; Neumann R
    J Ocul Pharmacol; 1994; 10(1):289-93. PubMed ID: 8207332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester.
    Bito LZ; Baroody RA
    Exp Eye Res; 1987 Feb; 44(2):217-26. PubMed ID: 3472899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.
    Howes J; Novack GD
    J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and ex vivo hydrolysis rates of ethacrynate esters and their relationship to intraocular pressure in the rabbit eye.
    Deshpande G; Schoenwald RD; Barfknecht CF; Duffel MW
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):539-56. PubMed ID: 11132901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs".
    Sloan KB; Perrin JH
    J Pharm Sci; 1994 Jul; 83(7):1066-8. PubMed ID: 7965668
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N; Bodor N; Wu WM
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application site dependent ocular absorption of timolol.
    Urtti A; Sendo T; Pipkin JD; Rork G; Repta AJ
    J Ocul Pharmacol; 1988; 4(4):335-43. PubMed ID: 3246568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.